样式: 排序: IF: - GO 导出 标记为已读
-
Esophageal Enigma: Isolated Lower Esophageal Sphincter Amyloidosis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-13 Alam Merchant M.D, Raul S. Gonzalez M.D, Anand Jain M.D
-
Validation of the THCC-RI predictive model for hepatocellular carcinoma in Asian cohort Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-13 Jeong-Ju Yoo, Young-Gi Song, Ji Eun Moon, Young Seok Kim, Sang Gyune Kim
-
Risk of Cancer in Patients with Diverticular Disease: A Population-based Cohort Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-13 Frederikke S. Troelsen, Dóra K. Farkas, Rune Erichsen, Lisa L. Strate, John A. Baron, Henrik T. Sørensen
Several studies have investigated the association between diverticular disease (DD) and colorectal cancer. However, whether there is an association between DD and malignancies other than those in the colorectum remains uncertain. For the 1978-2019 period, we conducted a nationwide, population-based cohort study using national Danish healthcare data. We followed DD patients for up to 20 years, beginning
-
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-10 Amrit K. Kamboj, Dhyanesh A. Patel, Rena Yadlapati
-
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-04 Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng, Kitty Yale
In phase 2 studies, efruxifermin, an Fc–FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatitis (NASH), now called metabolic dysfunction-associated steatohepatitis (MASH), for which there is no approved treatment. Type 2 diabetes (T2D) and obesity are prevalent among patients with MASH and increasingly treated with glucagon-like peptide-1 receptor
-
Prevalence of Gastric Precursor Lesions in Countries with Differential Gastric Cancer Burden: A Systematic Review & Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-02 Duco T. Mülder, Anne I. Hahn, Robert J. Huang, Margaret J. Zhou, Benjamin Blake, Omonefe Omofuma, John D. Murphy, Daniela S. Gutiérrez-Torres, Ann G. Zauber, James F. O’Mahony, M. Constanza Camargo, Uri Ladabaum, Jennifer M. Yeh, Chin Hur, Iris Lansdorp-Vogelaar, Reinier Meester, Monika Laszkowska
The prevalence of precursor lesions for gastric cancer (GC) and the differential burden between countries of varying GC risk is not well understood. We conducted a systematic review and meta-analysis to estimate the global prevalence of precursor lesions. We estimated the prevalence of atrophic gastritis (AG), gastric intestinal metaplasia (IM), and dysplasia in regions with low, medium, and high-GC
-
The Efficacy of Real-Time Computer-Aided Detection of Colonic Neoplasia In Community Practice: A Pragmatic Randomized Controlled Trial. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-02 Nikhil R. Thiruvengadam MD, Pejman Solaimani MD, Manish Shrestha MD, Seth Buller, Rachel Carson PA, Breanna Reyes-Garcia PA, Ronaldo D. Gnass MD, Bing Wang MD PhD, Natalie Albasha BS, Paul Leonor MD, Monica Saumoy MD MS, Raul Coimbra MD, Arnold Tabuenca MD, Wichit Srikureja MD, Steve Serrao MD MPH PhD
The use of computer-aided detection (CADe) has increased the adenoma detection rates (ADR) during colorectal cancer (CRC) screening/surveillance in randomized controlled trials (RCT) but has not shown benefit in real-world implementation studies. We performed a single-center pragmatic RCT to evaluate the impact of real-time CADe on ADR in colonoscopy performed by community gastroenterologists. We enrolled
-
The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-29 Jordan E. Axelrad MD MPH, David T. Rubin MD
-
Emotional Intelligence: An Impactful Yet Often Overlooked Skill That Can Enhance Physician Well-being and Professional Satisfaction Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 David J. Hass, Marc A. Brackett
-
Antibiotic exposure and risk of new-onset inflammatory bowel disease: a systematic review and dose-response meta-analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 Ruqiao Duan, Cunzheng Zhang, Gaonan Li, Jun Li, Liping Duan
The association between antibiotic exposure and inflammatory bowel disease (IBD) remains controversial, especially whether there is a dose-response relationship. We aimed to conduct a systematic review and meta-analysis to thoroughly evaluate the risk of new-onset IBD associated with antibiotic exposure. Four databases were searched from their inception to September 30, 2023, for all relevant studies
-
GLOBAL PREVALENCE OF PANCREATIC CYSTIC LESIONS IN THE GENERAL POPULATION ON MAGNETIC RESONANCE IMAGING: A SYSTEMATIC REVIEW AND META-ANALYSIS Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 Ana Vilela, Elit Quingalahua, Alejandra Vargas, Fadi Hawa, Carol Shannon, Eileen S. Carpenter, Jiaqi Shi, Somashekar G. Krishna, Un-Jung Lee, Jean M. Chalhoub, Jorge D. Machicado
Understanding the burden of pancreatic cystic lesions (PCLs) in the general population is important for clinicians and policymakers. In this systematic review, we sought to estimate the global prevalence of PCLs using magnetic resonance imaging (MRI) and to investigate factors that contribute to its variation. We searched MEDLINE, EMBASE, and Cochrane Central, from database inception through February
-
Defining Endoscopic Remission in Crohn’s Disease: MM-SES-CD and SES-CD Thresholds Associated with Low Risk of Disease Progression Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-28 Neeraj Narula, Emily C.L. Wong, Parambir S. Dulai, Jaiminkumar Patel, John K. Marshall, Clara Yzet, Vipul Jairath, Ryan Ungaro, Jean-Frederic Colombel, Walter Reinisch
We assessed Modified Multiplier Simple Endoscopic Score for Crohn’s disease (MM-SES-CD) and SES-CD thresholds that are best associated with low likelihood of long-term disease progression. Data from 61 patients with early CD who participated in the CALM long-term extension study were used as the derivation cohort and validated using the McMaster IBD database (n=99). The primary outcome was disease
-
Outcomes of high-grade immune checkpoint inhibitor hepatitis in hospitalized and non-hospitalized patients Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-23 Michael Li, Danny Wong, Jordan S. Sack, Alexander S. Vogel, F. Stephen Hodi, Lawrence Fong, Jennifer C. Lai, Stephen D. Zucker, Shilpa Grover
Guidelines recommend hospitalization for severe immune checkpoint inhibitor (ICI) hepatitis. We compared patient outcomes in the inpatient versus outpatient settings. We conducted a multicenter, retrospective cohort study of 294 ICI-treated patients who developed grade 3-4 ICI hepatitis. The primary outcome was time to ALT normalization (≤40); secondary outcomes included time to ALT≤100 U/L and time
-
AGA Clinical Practice Update on High-Quality Upper Endoscopy: Expert Review Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-22 Satish Nagula, Sravanthi Parasa, Loren Laine, Shailja C. Shah
-
-
-
Approaching Digestive Health Care in Transgender and Gender-Diverse Communities Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-21 Christopher Vélez, Kira L. Newman, Sonali Paul, Jens U. Berli, Vin Tangpricha, Laura E. Targownik
-
-
-
-
-
Global Epidemiology of Gallstones in the 21st Century: A Systematic Review and Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-19 Xin Wang, Wenqian Yu, Guoheng Jiang, Hongyu Li, Shiyi Li, Linjun Xie, Xuan Bai, Ping Cui, Qi Chen, YanMei Lou, Li Zou, SuLian Li, ZhongFang Zhou, Chi Zhang, Peng Sun, Mao Min
Gallstones are common and associated with substantial health and economic burden. We aimed to comprehensively evaluate the prevalence and incidence of gallstones in the 21st century. We systematically searched PubMed and Embase to identify studies reporting the prevalence and/or incidence of gallstones between January 1, 2000, and November 18, 2023. Pooled prevalence and incidence were calculated using
-
Biliary Neuroendocrine Tumor Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-17 Neil Khoury, Qian Wu, Murali Dharan
-
Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-17 Erica J. Brenner, Kimberly N. Weaver, Xian Zhang, Arthur J. Kastl, Jennifer A. Strople, Jeremy Adler, Marla C. Dubinsky, Athos Bousvaros, Runa Watkins, Xiangfeng Dai, Wenli Chen, Raymond K. Cross, Peter D.R. Higgins, Ryan C. Ungaro, Meenakshi Bewtra, Emanuelle A. Bellaguarda, Francis A. Farraye, Kelly Y. Chun, Michael Zikry, Monique Bastidas, Ann Firestine, Riley G. Craig, Margie E. Boccieri, Millie
COVID-19 vaccination prevents severe disease in most patients with inflammatory bowel disease (IBD), but immunosuppressive medications can blunt serologic response. We followed adults with IBD for >1 year post–COVID-19 vaccination to describe factors associated with SARS-CoV-2 infection after vaccination, evaluate for a protective SARS-CoV-2 antibody level, characterize SARS-CoV-2 antibody persistence
-
Dysphagia and Regurgitated Mass Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-16 Maunoo Lee, Saha Sadeghi, Ronald A. Mathiasen
-
Heartburn Relief Is the Major Unmet Need for Drug Development in Gastroesophageal Reflux Disease: Threshold Value Analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-16 Eric D. Shah, Michael A. Curley, Amit Patel, Wai-Kit Lo, Walter W. Chan
Heartburn symptoms contribute to healthcare-seeking among patients with gastroesophageal reflux disease (GERD). Despite clinical guidance, management is often dictated by insurance restrictions. Several potassium-competitive acid blockers (PCABs) are under development as a new class of therapy. We performed economic analyses to align GERD drug development with the needs of gastroenterologists, insurers
-
Association Between Celiac Disease and Irritable Bowel Syndrome: A Nationwide Cohort Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-16 Karl Mårild, Jonas Söderling, Benjamin Lebwohl, Peter H.R. Green, Hans Törnblom, Magnus Simrén, Kyle Staller, Ola Olén, Jonas F. Ludvigsson
The aim of this study was to determine the risk of irritable bowel syndrome (IBS) diagnosis in patients with celiac disease (CD) compared with general population comparators. Using Swedish histopathology and register-based data, we identified 27,262 patients with CD diagnosed in 2002–2017 and 132,922 age- and sex-matched general population comparators. Diagnoses of IBS were obtained from nationwide
-
Sex Differences and Immunoglobulin E Should Not Be Forgotten in Type 1 Autoimmune Pancreatitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 Wen-Feng Xia, Xiao-Ying Baia, Ai-Ming Yanga
-
Choosing a Comparator: Minimizing Baseline Differences Between Groups Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 Mary Andrews, Shirin Hemmat, Tram T. Tran
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 June Tome, Sahil Khanna, Darrell S. Pardi
-
Prescribing of Proton Pump Inhibitors for Prevention of Upper Gastrointestinal Bleeding in US Outpatient Visits Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 Jacob E. Kurlander, John N. Mafi, Michael J. Racz, Geoffrey D. Barnes, Sameer D. Saini, Patrick D. Meek, Gastrointestinal Bleeding Working Group, Elliot B. Tapper, Jeffrey T. Kullgren, Joel H. Rubenstein, Caroline R. Richardson, Danielle Helminski
-
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 Layla A. Abushamat, Pir Ahmad Shah, Robert H. Eckel, Stephen A. Harrison, Diana Barb
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1 in 3–4 adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Insulin resistance plays a central role in MASLD/MASH pathophysiology with higher rates of MASLD (2 in 3) and MASH with fibrosis (1 in 5) in adults with obesity and diabetes. This review summarizes the role of
-
Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 Mei-Hsuan Lee, Yi-Ting Chen, Yu-Han Huang, Sheng-Nan Lu, Tsai-Hsuan Yang, Jee-Fu Huang, Szu-Ching Yin, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, Hwai-I Yang, Hsuan-Yu Chen, Chien-Jen Chen
The impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on the development of cirrhosis and hepatocellular carcinoma (HCC) by chronic hepatitis B (CHB) or C infection and antiviral treatment statuses is not well-known. A total of 336,866 adults aged ≥30 years were prospectively enrolled in a health screening program between 1997–2013. MASLD was identified by abdominal ultrasonography
-
Multilevel Interventions to Improve Colorectal Cancer Screening in an Urban Native American Community: A Pilot Randomized Clinical Trial Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 Aasma Shaukat, Jack Wolf, Kyle Ryder, Jennifer P. Wisdom, Timothy R. Church
-
Assessment and Significance of Histologic Activity in Crohn’s Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-15 Alexandros D. Polydorides
-
Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-13 Junya Arai, Atsushi Miyawaki, Tomonori Aoki, Ryota Niikura, Yoku Hayakawa, Hiroaki Fujiwara, Sozaburo Ihara, Mitsuhiro Fujishiro, Masato Kasuga
Potassium-competitive acid blockers (PCABs) have been increasingly used to treat upper gastrointestinal disorders, replacing proton pump inhibitors (PPIs). Whereas PPIs are associated with an increased risk of gastric cancer (GC) after eradication, it is uncertain whether PCABs carry the same risk. Using a population-based claims database in Japan, we identified patients who were prescribed a clarithromycin-based
-
Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-13 Linhua Zheng, Siyuan Tian, Chunmei Yang, Bo Li, Gui Jia, Yansheng Liu, Ruiqing Sun, Xiufang Wang, Juan Deng, Miao Zhang, Lina Cui, Changcun Guo, Xinmin Zhou, Patrick S.C. Leung, Christopher L. Bowlus, M. Eric Gershwin, Yulong Shang, Ying Han
Hypercholesterolemia is frequently diagnosed in patients with primary biliary cholangitis (PBC). However, its association with the prognosis and lipid metabolism is unknown. In this study, we aimed to investigate the prognostic value of baseline total cholesterol (TC) levels in PBC and characterized the lipid metabolism. Of note, 531 patients with PBC without prior cirrhosis-related complications were
-
Dissecting Geographical and Racial Disparities in H. pylori Infection Rates: Screening and Eradication Strategies in the U.S. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-10 Yasutoshi Shiratori MD MPH PhD, Naoki Ishii MD MPH PhD, Anthony Kalloo MD
-
Glucagon-Like Peptide-1 Receptor Agonists in Patients With Cirrhosis: Answering the Unanswered Questions? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-10 Sara Mahgoub, Philip N. Newsome MD PhD
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-10 Markos Kalligeros MD, Eleftherios Mylonakis MD PhD, Mazen Noureddin MD
-
From ChatGPT to GutGPT: Enhancing AI for Personalized Health Care Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-10 Qingzhou Kong MD, Yueyue Li MD PhD, Yanqing Li MD PhD
-
Feasibility and Colonoscopy Yield Using the Fecal Immunochemical Test (FIT)-Based Colorectal Screening in a Latin America Country Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-09 Mauricio Paulin Sorbello, Ulysses Ribeiro Júnior, José Eluf-Neto, Vinicius Pfuetzenreiter, Afonso da Silva e Sousa Junior, Fábio Shiguehissa Kawaguti, Diane Dede Cohen, Evandro Sobroza de Mello, Sergio Carlos Nahas, Adriana Vaz Safatle-Ribeiro
Organized colorectal cancer (CRC) screening is not widely practiced in Latin America and the results of regional studies may help overcome barriers for implementation of national screening programs. We aimed to describe the implementation and findings of a fecal immunochemical test (FIT)-based program in Brazil. In a prospective population-based study, asymptomatic individuals (50–75 years old) from
-
Pathogenic variant IPMN tumors show increased tumor growth compared to those with familial pancreatic cancer kindreds: prognostic indicators. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-06 Mitchell S. Cappell, Martin Tobi
Abstract not available
-
Gastric Malignancies in United States in the Period From 2000 to 2018 Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-06 H, e, l, g, e, , L, ., , W, a, l, d, u, m
Abstract not available
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-05 Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao
Abstract not available
-
Low Colorectal Cancer Risk After Resection of High-Risk Pedunculated Polyps Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-05 Manuel Zorzi, Jessica Battagello, Claudio Barbiellini Amidei, Giulio Antonelli, Bastianello Germanà, Flavio Valiante, Stefano Benvenuti, Alberto Tringali, Francesco Bortoluzzi, Erica Cervellin, Davide Giacomin, Tamara Meggiato, Erik Rosa Rizzotto, Diego Fregonese, Manuela D’Incà, Gianluca Baldassarre, Paola Scalon, Maurizio Pantalena, Luisa Milan, Gianmarco Bulighin, Daniele Di Piramo, Maurizio Azzurro
Post–fecal immunochemical test (FIT) colonoscopy represents a setting with an enriched prevalence of advanced adenomas. Due to an expected higher risk of colorectal cancer (CRC), postpolypectomy surveillance is recommended, generating a substantially increased load on endoscopy services. The aim of our study was to investigate postpolypectomy CRC risk in a screening population of FIT+ subjects after
-
Biomarkers for Personalizing IBD Therapy: The Quest Continues Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-04 Raja Atreya, Markus F. Neurath
Despite recent advances in the understanding of the pathogenesis of inflammatory bowel diseases (IBD) and advent of multiple targeted therapies, approximately one-third of patients are primary non-responders to initiated treatment, and half of patients lose response over time. There is currently a lack of available biomarkers that would prognosticate therapeutic effectiveness of these advanced therapies
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-02 Mohammad Zamani, Shivani Shah Mattay, Siddharth Singh, Parakkal Deepak
Abstract not available
-
Scrutinizing ChatGPT Applications in Gastroenterology: A Call for Methodological Rigor to Define Accuracy and Preserve Privacy Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-02 Mauro Giuffrè, Dennis L. Shung
Abstract not available
-
Validated Clinical Score to Predict Gastroesophageal Reflux in Patients With Chronic Laryngeal Symptoms: COuGH RefluX Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-02 Amanda J. Krause, Alexander M. Kaizer, Dustin A. Carlson, Walter W. Chan, Chien-Lin Chen, C. Prakash Gyawali, Andrew Jenkins, John E. Pandolfino, Vinathi Polamraju, Ming-Wun Wong, Madeline Greytak, Rena Yadlapati
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-02 Rohit Loomba, Mohammad Zamani
Abstract not available
-
Validation of the Laryngeal Cognitive-Affective Tool Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-01 Amanda J. Krause, Tiffany Taft, Madeline Greytak, Zoe C. Burger, Erin Walsh, Philip Weissbrod, John E. Pandolfino, Rena Yadlapati
Cognitive-affective processes, including hypervigilance and symptom-specific anxiety, may contribute to chronic laryngeal symptoms and are potentially modifiable; however, a validated instrument to assess these constructs is lacking. The aims of this study were to develop and validate the Laryngeal Cognitive-Affective Tool (LCAT) instrument. This 2-phase single-center prospective study enrolled participants
-
Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-01 Xiang Peng, Jia-Yin Yao, Yu-qian Ma, Guo-hua Li, Huang-wei Chen, Yu Wan, Dong-sheng Liang, Min Zhang, Min Zhi
Previous studies confirm vonoprazan-amoxicillin effectiveness for . This study aims to investigate vonoprazan with varying amoxicillin dose and duration. This multicenter, prospective, randomized controlled, noninferiority trial enrolled patients with treatment naive infection from 5 clinical centers. Eligible participants were randomly assigned to H-VA-10 (vonoprazan 20 mg twice a day (b.i.d.) + amoxicillin
-
Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-01 Katarina Mitrova, Mette Julsgaard, Patrick Augustijns, Karin Cerna, Uma Mahadevan, Dana Duricova, Pregnancy Study Group, Raf Mols, Kristyna Zdychyncova, Michal Konecny, Philip O. Anderson, Milan Lukas
Abstract not available
-
Early Life and Childhood Environmental Exposures, More Than Genetic Predisposition, Influence Age of Diagnosis in a Diverse Cohort of 2952 Patients With IBD Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-02-01 Nidah S. Khakoo, Ashley H. Beecham, Jiangnan Lyu, Maria A. Quintero, Lissette Gomez, Maria T. Abreu, Amar R. Deshpande, David H. Kerman, Jacob L. McCauley, Siobhan Proksell, Oriana M. Damas
Inflammatory bowel disease (IBD) develops from a combination of genetic and environmental factors. The aim of this study was to determine the contribution of established environmental risk factors and genetic risk on age of IBD diagnosis in a diverse cohort. IBD patients in clinic completed detailed questionnaires. Blood was drawn for genetic analysis. Environmental risk factors and age of diagnosis
-
Pseudolipomatosis of the Colon Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-01-26 Jonathan Rozenberg, Adil Mir, Douglas Grider
Abstract not available
-
Upper GI Endoscopy Off PPI with Concurrent Telemetry Capsule pH monitoring. Evidence Based and Cost Effective Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-01-24 Philip O. Katz, Gaurav Ghosh
Abstract not available
-
Burden and Treatment of Chronic Upper GI Symptoms and Diagnoses – a Nationwide Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-01-24 Ava M. Sanayei, Chen Mo, Sarah Ballou, Nicole McHenry, Vikram Rangan, Prashant Singh, Johanna Iturrino, Anthony Lembo, Judy Nee
Background and Aims Chronic gastrointestinal (GI) symptoms are a common reason for seeking medical care. We aim to determine the rates of ambulatory care use and to characterize demographics, work up, and treatment (pharmacologic and nonpharmacologic) for patients chronic upper GI symptoms and conditions in the United States. Methods Estimates of annual visits for the most common upper GI symptoms
-
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19 Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-01-24 Cong Dai, Yu-hong Huang, Min Jiang
Abstract not available
-
Artificial Intelligence in Medical Consultations: Optimization in Assessment and Application Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-01-24 Qingzhou Kong, Yueyue Li
Abstract not available